期刊文献+

真性红细胞增多症患者JAK2 V617F基因突变及其意义 被引量:2

下载PDF
导出
摘要 目的研究真性红细胞增多症(PV)患者JAK2 V617F基因突变率及其与临床特征的相关性,同时探讨该突变在汉族和维吾尔族PV患者中的差异性。方法采用等位基因特异性PCR(AS-PCR)方法,对41例(维吾尔族19例,汉族22例)PV患者进行JAK2检测。结果 (1)41例PV患者中JAK2基因突变率82.9%(34/41)。22例汉族PV患者中突变阳性率为72.7%(16/22),19例维吾尔族PV患者中突变阳性率为94.7%(18/19),两族JAK2基因突变阳性率比较差异无统计学意义(P>0.05)。(2)中位随访51(3~142)个月后发现共4例PV患者转为骨髓纤维化,30例患者出现不同部位的血栓栓塞,11例患者出现不同程度的出血;JAK2阳性患者血栓事件发生率较阴性者高(P<0.05),但两个民族间差异无统计学意义(P>0.05);出血并发症及转化在JAK2阳性与阴性及汉族与维吾尔族PV患者中差异均无统计学意义(P>0.05)。结论 PV患者中有较高的JAK2 V617F基因突变率,汉族与维吾尔族PV患者该基因突变率及相关并发症间无明显差异。
出处 《广东医学》 CAS CSCD 北大核心 2013年第1期94-96,共3页 Guangdong Medical Journal
基金 新疆维吾尔自治区科技支疆项目计划(指令性)项目(编号:200991142)
  • 相关文献

参考文献12

  • 1KURDI M,BOOZ G W. JAK redux:a second look at the regulation and role of JAKs in the heart[J].American Journal of Physiology-Heart and Circulatory Physiology,2009,(02):H1545-H1556. 被引量:1
  • 2GHORESCHI K,LAURENCE A,O'SHEA J J. Janus kinases in immune cell signaling[J].Immunological Reviews,2009,(01):273-287.doi:10.1111/j.1600-065X.2008.00754.x. 被引量:1
  • 3TEFFERI A,VARDIMAN J W. Classification and diagnosis of myeloproliferative neoplasms:the 2008 World Health Organization criteria and point-of-care diagnostic algorithms[J].Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research Fund,U.K,2008,(01):14-22. 被引量:1
  • 4BAXTER E J,SCOTT L M,CAMPELL P J. Acquired mutation of the tyrosine kinase JAK2 in human myelop roliferative di sorders[J].The Lancet,2005,(9464):1054-1061. 被引量:1
  • 5UGO V,MARZAC C,TEYSSANDIER I. Multiple signaling pathways are involved in erythropoietin independent differentiation of erythroid progenitors in polycythemia vera[J].Experimental Hematology,2004,(02):179-187. 被引量:1
  • 6JAMES C,UGO V,LE COUEDIC J P. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera[J].Nature,2005,(03):1144-1148. 被引量:1
  • 7张励,尤婷玉,马茉娇,刘小宇,王伟.JKA2V617F点突变在BCR-ABL阴性骨髓增生性疾病中的意义[J].临床军医杂志,2011,39(1):192-193. 被引量:2
  • 8CAMPBELL P J,GRIESSHAMMER M,DOHNER K. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis[J].Blood,2005,(05):2098-2100. 被引量:1
  • 9McCLURE R,MAI M,LASHO T. Validation of two clinically useful assays for evolution of JAK2-V617F mutation in chronic myeloproliferative disorders[J].Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research Fund,U.K,2006,(01):168-171. 被引量:1
  • 10夏亮,吴竞生,丁凯阳,蔡晓燕,朱微波,曾庆曙,刘欣,皖湘,武琳琳.87例骨髓增殖性肿瘤患者JAK2及MPL基因突变位点研究[J].临床血液学杂志,2010,23(1):16-19. 被引量:14

二级参考文献10

共引文献14

同被引文献20

  • 1Mcclure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders[J]. Leukemia, 2006, 20(1) :168 -171. 被引量:1
  • 2Lehot JJ ,Was B,Denddeu I., etal. Oxygenator thrombo- sis without heparin resistance in polycythemia vera[J]. Ann Fr Anesth Reanim, 2012,31 Suppl 1 : S14- 17. 被引量:1
  • 3Ural AU,Cetin T, Aveu F. Antithrombotic challenges af- ter coronary artery surgery in patients with polyeytemia vera[J]. Card Surg,2008,23(4):410. 被引量:1
  • 4Fantasia F, Di Capua EN, Cenfra N ,et al. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F ex- pression levels and control genes in Ph-negative myeloproliferative neo- plasms [ J ] Ann Hematol,2013,93 (4) :609-616. 被引量:1
  • 5Tefferi A, Vainchenker W. myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strat- egies[J]. J Clin Oncol,2011,29(5) :573-582. 被引量:1
  • 6Boissinot M, Cleyrat C, Vilaine M, et al. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-I 1 are over-expressed in Pol- ycythemia vera and contribute to the growth of clonal crythoblasts in- dependently of JAK2 V617 F [ J ]. Oncogene, 2011,30 ( 8 ) :990 -1001. 被引量:1
  • 7Kerguel6n Fuentes AE, HernOndez-Maraver D, Lombardia L, et al. Clinical significance of the quantification of JAK2V617F allele bur- den in classical Ph-negative myeloproliferative neoplasma [ J ] Med Cfin(Barc) ,2012,139(9) :373-378. 被引量:1
  • 8廖克龙,杨康,张伟,王海东.冠状动脉旁路移植术治疗重症冠心病25例临床分析[J].重庆医学,2008,37(4):355-356. 被引量:5
  • 9夏亮,吴竞生,丁凯阳,蔡晓燕,朱微波,曾庆曙,刘欣,皖湘,武琳琳.87例骨髓增殖性肿瘤患者JAK2及MPL基因突变位点研究[J].临床血液学杂志,2010,23(1):16-19. 被引量:14
  • 10丰明俊,陈晓敏,储慧民.真性红细胞增多症并发心脏改变1例报告[J].浙江医学,2010(9):1424-1425. 被引量:1

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部